{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:02:14Z","timestamp":1778648534538,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biotechadv.2022.107986","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T13:42:31Z","timestamp":1652967751000},"page":"107986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein"],"prefix":"10.1016","volume":"59","author":[{"given":"Carlos F.S.","family":"Costa","sequence":"first","affiliation":[]},{"given":"Arm\u00e9nio J.M.","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Ana Margarida G.C.","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Ana Cec\u00edlia A.","family":"Roque","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.biotechadv.2022.107986_bb0005","article-title":"A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies","author":"Acharya","year":"2020","journal-title":"bioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jchromb.2016.07.035","article-title":"Petasis-Ugi ligands: new affinity tools for the enrichment of phosphorylated peptides","volume":"1031","author":"Batalha","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0025","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1039\/C9OB00564A","article-title":"\u03b2-Hairpins as peptidomimetics of human phosphoprotein-binding domains","volume":"17","author":"Batalha","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0030","first-page":"1","article-title":"SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface","volume":"121577","author":"Bertoglio","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0035","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist\u2019s guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","article-title":"Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2","volume":"17","author":"Bracken","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0060","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.chom.2021.06.008","article-title":"Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease","volume":"29","author":"Case","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0065","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0070","article-title":"Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants Hyeseon","author":"Cho","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0075","series-title":"List of the Structures of S-Protein in Complex with Ligands Deposited in the Protein Data Bank until the 1st January 2021","author":"Costa","year":"2021"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0080","series-title":"Analysis of the Interacting Residues between Wild Type SARS-CoV-2 Spike Protein and Natural Ligand hACE2, As Well as Three Engineered Alternative Ligands","author":"Costa","year":"2022"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19204-y","article-title":"Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2","volume":"11","author":"Cust\u00f3dio","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03461-y","article-title":"Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice","author":"De Gasparo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/bit.26090","article-title":"The future of protein scaffolds as affinity reagents for purification","volume":"114","author":"Dias","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0100","doi-asserted-by":"crossref","DOI":"10.1039\/C4RA16934D","article-title":"An in silico and chemical approach towards small protein production and application in phosphoproteomics","volume":"5","author":"Dias","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0105","doi-asserted-by":"crossref","first-page":"68979","DOI":"10.1039\/C6RA10900D","article-title":"Affinity adsorbents for proline-rich peptide sequences: a new role for WW domains","volume":"6","author":"Dias","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0110","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","article-title":"Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail","volume":"6","author":"Dong","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","article-title":"Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy","volume":"183","author":"Du","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0120","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41423-021-00752-2","article-title":"Neutralizing antibodies for the prevention and treatment of COVID-19","volume":"18","author":"Du","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0125","author":"Eurpean Medicines Agency"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0130","series-title":"Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies","author":"Finkelstein","year":"2021"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0135","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.1021\/acs.jpcb.0c05994","article-title":"Critical sequence hotspots for binding of novel coronavirus to angiotensin converter enzyme as evaluated by molecular simulations","volume":"124","author":"Ghorbani","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0140","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41587-020-0687-9","article-title":"Animal-free alternatives and the antibody iceberg","volume":"38","author":"Gray","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26401-w","article-title":"Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27610-z","article-title":"A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo","volume":"13","author":"Hanke","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0160","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science (80-.)."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0165","article-title":"Molecular basis of SARS-CoV-2 Omicron variant receptor engagement and antibody evasion and neutralization","author":"Hong","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0170","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0175","article-title":"Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation","author":"Hurlburt","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0180","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0190","first-page":"1","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0195","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 Hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0205","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.abe0075","article-title":"De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2","volume":"370","author":"Linsky","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0215","article-title":"Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0220","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0225","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","article-title":"The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections","volume":"15","author":"Machhi","year":"2020","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 omicron variant: antibody evasion and cryo-EM structure of spike protein\u2013ACE2 complex","author":"Mannar","year":"2022","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 omicron immune evasion and receptor engagement","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0240","article-title":"Characterization of structural and energetic differences between conformations of the SARS-CoV-2 spike protein","author":"Moreira","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0245","series-title":"COVID-19 Treatment Guidelines","article-title":"Anti-SARS-CoV-2 monoclonal antibodies | COVID-19 treatment guidelines","author":"NIH","year":"2022"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0250","first-page":"1","article-title":"Discovery of cyclic peptide ligands to the SARS-CoV-2 spike protein using mRNA display","volume":"2","author":"Norman","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0255","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and Immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0260","article-title":"Scanning the RBD-ACE2 molecular interactions in Omicron variant","author":"Rath","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0265","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.tips.2020.07.004","article-title":"Fruitful neutralizing antibody pipeline brings Hope to defeat SARS-Cov-2","volume":"41","author":"Renn","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0270","article-title":"Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants","author":"Rothenberger","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0275","first-page":"1","article-title":"Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers","volume":"12","author":"Rujas","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 spike protein: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101403","article-title":"Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs","volume":"298","author":"Schilling","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0290","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.abe3255","article-title":"An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive spike","volume":"370","author":"Schoof","year":"2021","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0295","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/d41586-021-02039-y","article-title":"How the coronavirus infects cells - and why Delta is so dangerous","volume":"595","author":"Scudellari","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0300","article-title":"Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies","author":"Shah","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637651","article-title":"The Case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic","volume":"12","author":"Shah","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: perspectives on the future trajectory of COVID-19","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0320","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0325","article-title":"Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor","author":"Veeramachaneni","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0335","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0340","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41422-020-00446-w","article-title":"Structure-based development of human antibody cocktails against SARS-CoV-2","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0350","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.04.042","article-title":"Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies","volume":"184","author":"Williams","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0360","series-title":"WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data","first-page":"1","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0365","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0370","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0375","article-title":"An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain","author":"Wu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0380","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2021","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0385","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41422-020-00444-y","article-title":"Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection","volume":"31","author":"Yao","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0390","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","article-title":"The proteins of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19","volume":"39","author":"Yoshimoto","year":"2020","journal-title":"Protein J."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0395","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0400","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biotechadv.2022.107986_bb0405","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41564-021-00954-4","article-title":"SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution","volume":"6","author":"Zahradn\u00edk","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0410","first-page":"6","article-title":"Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0415","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","article-title":"Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient","volume":"27","author":"Zhou","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biotechadv.2022.107986_bb0420","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975022000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975022000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:13:28Z","timestamp":1760012008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975022000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":84,"alternative-id":["S0734975022000829"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2022.107986","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2022.107986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107986"}}